Bausch & Lomb Corp (BLCO) · Oct 28, 2026 · Earnings

Bausch + Lomb earnings beat as 2026 EBITDA guidance jumps

Beat — Adjusted EPS $0.34 vs ~$0.21 consensus

Bausch + Lomb’s Q3 earnings beat on adjusted EPS, with all three segments growing and full-year EBITDA guidance raised sharply.

Bausch + Lomb is executing a broad-based eye-health growth plan across contact lenses, surgical products and pharmaceuticals, with MIEBO, premium intraocular lenses and daily contact lenses among the current growth drivers. Its stated longer-term plan targets 5–7% constant-currency revenue growth and margin expansion through 2028.

The quarter materially exceeded the earnings bar. Adjusted EPS was $0.34 versus published consensus of roughly $0.21, while revenue of $1.375 billion was essentially in line with the roughly $1.37 billion expectation.

MetricQ3 2026Q3 2025External expectation
Revenue$1.375B$1.281B~$1.37B
Adjusted EPS$0.34$0.18~$0.21
Adjusted EBITDA$325M$243M—
Operating cash flow$233M$137M—
Full-year revenue guidance$5.450B–$5.550B—Prior: $5.440B–$5.540B
Full-year adjusted EBITDA excluding acquired IPR&D$1.090B–$1.140B—Prior: $1.025B–$1.075B

Growth was broad rather than dependent on one segment. Vision Care rose 5% reported and 6% constant currency, Surgical increased 9%, and Pharmaceuticals grew 11%, with the company citing daily SiHy and ULTRA contact lenses, premium IOLs and MIEBO as key drivers.

The more important surprise is operating leverage. Operating income rose to $155 million from $95 million, adjusted EBITDA climbed to $325 million from $243 million, and operating cash flow increased to $233 million from $137 million.

Management raised the full-year outlook beyond the prior quarter’s increase. Revenue guidance moved only modestly higher, but adjusted EBITDA guidance jumped by $65 million at both ends of the range, implying that the company sees stronger underlying performance and profitability rather than merely better currency. The filing says the revenue range includes a $15 million improvement in the underlying business outlook, partly offset by $5 million less expected currency benefit.

Bottom line: This is a meaningful upgrade to the business story: revenue landed near expectations, but profitability and cash generation materially outperformed, prompting another sizable EBITDA guidance increase. The quarter strengthens the case that Bausch + Lomb’s growth plan is translating into operating leverage, not just sales growth.

Original filing on SEC EDGAR

More Bausch & Lomb Corp news

Bausch + Lomb earnings beat as 2026 EBITDA guidance jumps | BLCO Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.